Jade Biosciences, Inc.
NASDAQ:JBIO · NASDAQ Global Market
-$0.21 today
Vol 3.28M · Avg 0.83M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:JBIO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$129.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.12, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $282.0K +193.8% | $96.0K +41.2% | $68.0K +353.3% | $15.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$282.0K -193.8% | -$96.0K -41.2% | -$68.0K -353.3% | -$15.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $93.1M +75.1% | $53.2M -17.2% | $64.2M +66.3% | $38.6M +157.7% | $15.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.4M -3.3% | $21.1M +23.6% | $17.1M +17.5% | $14.5M +81.4% | $8.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $113.5M +52.8% | $74.3M -8.6% | $81.3M +52.9% | $53.2M +131.1% | $23.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $26.0K -90.8% | $282.0K +193.8% | $96.0K +41.2% | $68.0K +353.3% | $15.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$127.3M -83.8% | -$69.3M +8.1% | -$75.4M -46.6% | -$51.4M -124.1% | -$22.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$113.5M -52.2% | -$74.6M +8.4% | -$81.4M -52.9% | -$53.2M -131.2% | -$23.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $7.8M +54.3% | $5.0M -15.2% | $5.9M +224.9% | $1.8M +2715.4% | $65.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$13.8M -374.9% | $5.0M -15.5% | $5.9M +239.5% | $1.8M +2724.2% | $62.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$127.4M -83.0% | -$69.6M +7.8% | -$75.5M -46.6% | -$51.5M -124.2% | -$23.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $58.0K +5.5% | $55.0K -1.8% | $56.0K +124.0% | $25.0K +733.3% | $3.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$127.4M -83.0% | -$69.6M +7.8% | -$75.5M -46.6% | -$51.5M -124.3% | -$23.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 +95.2% | -$85 +15.1% | -$100 -36.3% | -$74 -123.5% | -$33 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 +95.2% | -$85 +15.1% | -$100 -36.3% | -$74 -123.5% | -$33 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $31.4M +3740.1% | $816.6K +8.5% | $752.3K +7.6% | $699.2K +0.3% | $697.4K | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $31.4M +3740.1% | $816.6K +8.5% | $752.3K +7.6% | $699.2K +0.3% | $697.4K | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tectonic Therapeutic, Inc.
NASDAQ:TECX
$561.74M
XOMA Royalty Corp.
NASDAQ:XOMA
$525.59M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$440.41M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$351.21M
Silence Therapeutics plc
NASDAQ:SLN
$324.97M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$296.11M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
Genelux Corporation
NASDAQ:GNLX
$109.47M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does JBIO generate?
Jade Biosciences, Inc. (JBIO) reported $0.00 of revenue in fiscal 2025.
Is JBIO profitable?
Jade Biosciences, Inc. (JBIO) reported -$127,410,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.